TY - JOUR
T1 - Balloon-occluded transarterial chemoembolization using a 1.8-French tip Coaxial microballoon catheter for hepatocellular carcinoma
T2 - Technical and safety considerations
AU - Matsumoto, Tomohiro
AU - Endo, Jun
AU - Hashida, Kazunobu
AU - Ichikawa, Hitoshi
AU - Kojima, Seiichiro
AU - Takashimizu, Shinji
AU - Watanabe, Norihito
AU - Yamagami, Takuji
AU - Hasebe, Terumitsu
N1 - Publisher Copyright:
© 2014 Informa Healthcare.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Objective: To evaluate the technical feasibility and safety considerations of balloon-occluded transarterial chemoembolization (B-TACE) using a newly developed 1.8-French (Fr) tip microballoon catheter for hepatocellular carcinoma (HCC). Material and methods: Between February 2013 and May 2013, 31 patients (20 males, 11 females; age range 56-85 years) underwent B-TACE using a 1.8-Fr tip microballoon catheter for unresectable HCC. The technical success rate, procedural complications, and adverse events of B-TACE were retrospectively investigated. Results: A total of 31 patients were subjected to 70 sessions of B-TACE using a 1.8-Fr tip microballoon catheter. The level of B-TACE was sub-subsegmental in 11, subsegmental in 35, segmental in 14, lobar in five, and right inferior phrenic artery in five sessions. The overall technical success rate was 99% (69 out of 70 sessions). As procedural complications, rupturing of the microballoon (n = 3) and aneurysmal dilatation at the site of balloon occlusion (n = 2) were encountered. There were no significant differences in any parameters between blood biochemical examination before and between two to four weeks after the procedure. Conclusion: A 1.8-Fr tip microballoon catheter enables selective catheterization in patients with HCC and B-TACE using the 1.8-Fr tip microballoon catheter is a safe procedure.
AB - Objective: To evaluate the technical feasibility and safety considerations of balloon-occluded transarterial chemoembolization (B-TACE) using a newly developed 1.8-French (Fr) tip microballoon catheter for hepatocellular carcinoma (HCC). Material and methods: Between February 2013 and May 2013, 31 patients (20 males, 11 females; age range 56-85 years) underwent B-TACE using a 1.8-Fr tip microballoon catheter for unresectable HCC. The technical success rate, procedural complications, and adverse events of B-TACE were retrospectively investigated. Results: A total of 31 patients were subjected to 70 sessions of B-TACE using a 1.8-Fr tip microballoon catheter. The level of B-TACE was sub-subsegmental in 11, subsegmental in 35, segmental in 14, lobar in five, and right inferior phrenic artery in five sessions. The overall technical success rate was 99% (69 out of 70 sessions). As procedural complications, rupturing of the microballoon (n = 3) and aneurysmal dilatation at the site of balloon occlusion (n = 2) were encountered. There were no significant differences in any parameters between blood biochemical examination before and between two to four weeks after the procedure. Conclusion: A 1.8-Fr tip microballoon catheter enables selective catheterization in patients with HCC and B-TACE using the 1.8-Fr tip microballoon catheter is a safe procedure.
KW - Balloon-occluded transarterial chemoembolization
KW - Catheter interventions
KW - Hepatocellular carcinoma
KW - Interventional radiology
KW - Microballoon catheter
KW - Minimally invasive procedures
UR - http://www.scopus.com/inward/record.url?scp=84924804460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924804460&partnerID=8YFLogxK
U2 - 10.3109/13645706.2014.951657
DO - 10.3109/13645706.2014.951657
M3 - Article
C2 - 25263680
AN - SCOPUS:84924804460
SN - 1364-5706
VL - 24
SP - 94
EP - 100
JO - Endoscopic surgery and allied technologies
JF - Endoscopic surgery and allied technologies
IS - 2
ER -